The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates

Journal of Rheumatology

Volumn 23, Issue SUPPL. 44, 1996, Pages 47-51

  Yelin, Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Costs; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; HEALTH SURVEY; REVIEW;

ARTHRITIS, RHEUMATOID; HEALTH CARE COSTS; HEALTH SURVEYS; HUMANS;

EID: 0029915675     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Meenan R, Yelin E, Henke C, Curtis D, Epstein W The costs of rheumatoid arthritis Arthritis Rheum 1989;21:827-33.
2. Lubeck D, Spitz P, Fries J, Wolfe F, Mitchell D, Roth S: A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
3. Liang M, Larson M, Thompson M, et al: Cost and outcomes in rheumatoid and osteoarthritis. Arthritis Rheum 1984;27:522-9.
4. Allaire S, Prashker M, Meenan R: The cost of rheumatoid arthritis Pharmacoeconomics, 1994;6:513-22.
5. Felts W, Yelin E: The economic impact of the rheumatic diseases in the United States J Rheumatol 1989;16:867-84.
6. Yelin E, Callahan L: The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-62.
7. Prashker M, Meenan R: The total costs of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
8. Bergquist S, Felson D, Prashker M, Freedberg K: The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995;38:326-33.
9. Laupacis A, Feeny D, Detsky A, Tugwell P: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic associations. Can Med Assoc J 1992;146:473-81.
10. Yelin E, Henke C, Kramer J, Nevitt M, Shearn M, Epstein W: A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. New Engl J Med 1985;312:962-7.
11. Yelin E, Shearn M, Epstein W: Health outcomes for a chronic disease in pre-paid group practice and fee-for-service settings: The case of rheumatoid arthritis. Med Care 1986;24:236-47.
12. Criswell LA, Henke CJ: What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-35.